Neurocentrx appoints two members to the board

Neurocentrx, a UK-based pharmaceutical company, has appointed Nigel Brooksby (pictured right) as non-executive chairman.

Brooksby brings experience in business and growth strategy across the healthcare sector having held senior global positions at Pfizer, Sanofi and Wellcome - now GSK.

His career history has seen him work in private equity and venture capital and he has been president of the ABPI.

Brooksby said: “My focus is to accelerate the business model and drive commercial clinical trials to raise international awareness of what we are offering, and enter the global market.

“I look forward to working the team, and helping to drive the company to an exciting new stage in their development.”

Joining Brooksby is EUSA Pharma’s former chief medical officer Dr Tim Corn, who becomes the pharma group’s non-executive director.

Carmel Reilly, chief executive officer of Neurocentrx, said: “I am honoured to welcome the extraordinary talents of Nigel and Tim onto the board.

“This is an important milestone for Neurocentrx and marks the start of an exciting new phase of our growth.”